Musical Chairs Continues at InVivo with New Interim CFO

Last week we covered the sudden departure of InVivo’s CFO Sean Moran. At that time the (interim) CEO Michael Astrue took interim charge of the role. Now a week later the company tells us that Gregory D. Perry has taken up the position, although again on an interim basis. Mr. Perry was most recently the Executive Vice President and CFO of Immunogen, Inc. prior to which he served as CFO of Elixir Pharmaceuticals, Inc. from 2007 to 2009.

“We are excited to bring on board a CFO with the integrity, talent and experience of Greg Perry,” said Mike Astrue, the interim CEO of InVivo. “His breadth of experience can add value to InVivo in a variety of ways.”

The company’s share price hasn’t recovered from the recent bad news about the delayed market approval of its biopolymer spinal scaffold. At the time of going to press it’s languishing at $1.37 compared with $5.50 a month or so ago.